CD27 CAR-T

CD27 CAR-T is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD70, a surface protein upregulated in high-risk and relapsed multiple myeloma. Unlike traditional CAR-Ts that use single-chain variable fragments (scFv) for antigen binding, this construct utilizes a truncated fragment of CD27, the natural ligand for CD70, as the extracellular binding domain. Preclinical studies conducted by researchers at the University of California San Francisco and Emory University demonstrate that this ligand-based approach provides superior expansion and persistence compared to scFv-based designs. The therapy is being developed to address unmet needs in patients with high-risk genotypes, such as t(4;14) and gain 1q, where CD70 expression is significantly elevated.

Other names

CD27-based CAR-TCD-27-based CAR-TCD 27-based CAR-TCD70-targeted CD27 CAR-TCD-70-targeted CD27 CAR-TCD 70-targeted CD27 CAR-Tnatural ligand-based CAR-T